Investigations and management of chronic cough: A 2020 update from the ERS Chronic Cough Task Force

Mohammed A. M. Farooqi, Vicky Cheng, Mustafaa Wahab, Izza Shahid, Paul M. O’Byrne, Imran Satia

Full article

A PDF of the full version of the article can be accessed free of charge through the website of Polish Archives of Internal Medicine.


Chronic cough affects approximately 10% of the general population, is highest amongst people aged 50 to 60 years, and is twice as common in women than men. It is described to last 8 weeks or longer in adults and does not respond well to treatment with over-the-counter medications and those targeting potential associated conditions. This is a debilitating condition with physical, social, and psychological consequences.

The purpose of this review was to highlight the key messages on the management of chronic cough from the task force commissioned by the European Respiratory Society. The assessment of patients with chronic cough should include a thorough detailed history and examination to identify potential causes. The impact and severity can be assessed in a clinic using questionnaires. Potential causes of the condition vary and include, for example, angiotensin-converting enzyme inhibitors, smoking, asthma, nonasthmatic eosinophilic bronchitis, gastroesophageal reflux disease, and upper airways cough syndrome.

In many patients, coughing is persistent despite optimum medical therapy of the underlying medical condition and is hence referred to as refractory chronic cough. In some cases, no cause can be found and the cough is classified as unexplained chronic cough. If treatment of any underlying disease is unsuccessful at controlling cough, then neuromodulatory treatment such as a low-dose opioid, gabapentin, pregabalin, or speech and language therapy may be considered. There is no licensed treatment for chronic cough, but a new class of treatment targeting the purinergic P2X3 receptor is currently in phase 2 and 3 of development.

See also
  • Human-important outcomes and EBM during the COVID-19 pandemic The pandemic brought with it an entire new realm of human suffering that is only indirectly related to disease itself—it relates to the societies’ ways of dealing with the illness. We propose that when making decisions about health-care interventions during this and during future pandemics, those “human-important outcomes” are carefully considered.
  • Management of chronic cough Dr Imran Satia, assistant professor in the Division of Respirology at McMaster University and researcher of chronic cough, discusses the practical relevance of the current definitions and management guidelines in chronic cough.
  • Aspirin for primary cardiovascular prevention: Why the wonder drug should not be precipitously dismissed This review provides an overview of the available evidence on aspirin for primary cardiovascular prevention, focusing on the results of meta-analyses and strengths and pitfalls of meta-analytic assessments.
  • Reinvigorating the clinical examination for the 21st century In the modern American hospital, clinicians spend as little as 12% of their time in direct contact with patients and their families. This has led to a decline in clinical examination skills and contributes to diagnostic error. In 2017, the Society of Bedside Medicine was formed to encourage innovation, education, and research on the role of the clinical encounter in 21st century medicine.
  • Risk mitigation for travelers: Managing endemic and emerging threats International travel has become an increasingly complex issue as a risk factor for infectious diseases. This review examines important considerations when evaluating travelers, with a special focus on the risk of emerging infectious diseases, by placing clinical syndromes in a travel context.
  • Thyroid emergencies This review discusses the clinical presentation, diagnosis, and management of patients presenting with myxedema coma or thyroid storm. If not promptly and appropriately diagnosed and treated, both conditions are associated with poor outcomes and high mortality rates.

We would love to hear from you

Comments, mistakes, suggestions?

We use cookies to ensure you get the best browsing experience on our website. Refer to our Cookies Information and Privacy Policy for more details.